10月16日，英派药业-B盘中上涨9.03%，报14.12港元，成交额3870.87万港元。
消息面上，公司核心产品塞纳帕利此前获得欧洲药品管理局人用药品委员会积极意见，建议批准其用于晚期上皮性卵巢癌、输卵管癌及原发性腹膜癌的一线维持治疗，后续将提交欧盟委员会作最终决定。
此外，公司9月已纳入沪深港通，叠加上半年收入1.05亿元、同比增长316.8%，核心产品商业化与国际化进展共同支撑市场情绪。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.